耳鼻咽喉科・頭頸部外科85巻7号

2013年06月発行

特集 分子標的薬時代の耳鼻咽喉科診療―処方するとき，服用患者を診るときのポイント ≪頭頸部癌に対する分子標的薬治療≫

頭頸部癌に対する分子標的薬の将来展望―セツキシマブのほかには何があるのか

著者： 清田尚臣¹

所属機関： ¹神戸大学大学院医学研究科内科学講座腫瘍・血液内科学分野

ページ範囲：P.488 - P.492

POINT

●標的分子としてのerbBファミリーの可能性

●標的分子としてのVEGFの可能性

●erbBファミリーおよびVEGF以外の標的分子

参考文献

1）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359：1116-1127, 2008

2）Machiels JP, et al：Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy：an open-label, randomised phase 3 trial. Lancet Oncol 12：333-343, 2011

3）Mitsudomi T, et al：Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label, randomised phase 3 trial. Lancet Oncol 11：121-128, 2010

4）Maemondo M, et al：Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362：2380-2388, 2010

5）Stewart JS, et al：Phase Ⅲ study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck［corrected］. J Clin Oncol 27：1864-1871, 2009

6）Shepherd FA, et al：Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353：123-132, 2005

7）Soulieres D, et al：Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22：77-85, 2004

8）Siu LL, et al：Phase Ⅰ/Ⅱ trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck：a Princess Margaret Hospital phase Ⅱ consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25：2178-2183, 2007

9）Cohen EE, et al：Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck：a phase Ⅰ/Ⅱ study. Lancet Oncol 10：247-257, 2009

10）Slamon DJ, et al：Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344：783-792, 2001

11）Bang YJ, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

12）Kalyankrishna S, et al：Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24：2666-2672, 2006

13）de Souza JA, et al：A phase Ⅱ study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18：2336-2343, 2012

14）Yang JC, et al：Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations（LUX-Lung 2）：a phase 2 trial. Lancet Oncol 13：539-548, 2012

15）Argiris A, et al：Phase Ⅱ trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 29：1140-1145, 2011

16）Williamson SK, et al：Phase Ⅱ evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck：Southwest Oncology Group Study S0420. J Clin Oncol 28：3330-3335, 2010

17）Machiels JP, et al：Phase Ⅱ study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck：GORTEC 2006-01. J Clin Oncol 28：21-28, 2010

18）Schmitz S, et al：Phase Ⅱ study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck：clinical activity and molecular response（GORTEC 2008-02）. Ann Oncol 23：2153-2161, 2012

19）Brooks HD, et al：Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117：2112-2119, 2011

20）Kwak EL, et al：Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363：1693-1703, 2010